Evidence map›Paper›PMID 25148595›Full record

ArticleJournal of chemical information and modeling2014

Structure-based virtual screening of the nociceptin receptor: hybrid docking and shape-based approaches for improved hit identification.

Pankaj R Daga, Willma E Polgar, Nurulain T Zaveri

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. New Technologies for Elucidating Opioid Receptor Function.Trends in pharmacological sciences · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Pankaj R DagaAstraea Therapeutics, LLC. , 320 Logue Avenue, Mountain View, California 94043, United States.
Willma E Polgar
Nurulain T Zaveri
Astraea Therapeutics (United States) · USSRI International · US

Funding

DISCOVERY OF SMALL-MOLECULE ORPHANIN FQ RECEPTOR LIGANDSR01DA014026 · NIDA · SRI INTERNATIONAL · PI ZAVERI, NURULAIN T · 2001 to 2011
$3.4M
Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse TherapyR01DA027811 · NIDA · ASTRAEA THERAPEUTICS, LLC · PI ZAVERI, NURULAIN T · 2009 to 2014
$3.4M
NIDA NIH HHS R01 DA014026NIDA NIH HHS R01 DA027811
6 · The paper itself

Abstract

The antagonist-bound crystal structure of the nociceptin receptor (NOP), from the opioid receptor family, was recently reported along with those of the other opioid receptors bound to opioid antagonists. We recently reported the first homology model of the 'active-state' of the NOP receptor, which when docked with 'agonist' ligands showed differences in the TM helices and residues, consistent with GPCR activation after agonist binding. In this study, we explored the use of the active-state NOP homology model for structure-based virtual screening to discover NOP ligands containing new chemical scaffolds. Several NOP agonist and antagonist ligands previously reported are based on a common piperidine scaffold. Given the structure-activity relationships for known NOP ligands, we developed a hybrid method that combines a structure-based and ligand-based approach, utilizing the active-state NOP receptor as well as the pharmacophoric features of known NOP ligands, to identify novel NOP binding scaffolds by virtual screening. Multiple conformations of the NOP active site including the flexible second extracellular loop (EL2) loop were generated by simulated annealing and ranked using enrichment factor (EF) analysis and a ligand-decoy dataset containing known NOP agonist ligands. The enrichment factors were further improved by combining shape-based screening of this ligand-decoy dataset and calculation of consensus scores. This combined structure-based and ligand-based EF analysis yielded higher enrichment factors than the individual methods, suggesting the effectiveness of the hybrid approach. Virtual screening of the CNS Permeable subset of the ZINC database was carried out using the above-mentioned hybrid approach in a tiered fashion utilizing a ligand pharmacophore-based filtering step, followed by structure-based virtual screening using the refined NOP active-state models from the enrichment analysis. Determination of the NOP receptor binding affinity of a selected set of top-scoring hits resulted in identification of several compounds with measurable binding affinity at the NOP receptor, one of which had a new chemotype for NOP receptor binding. The hybrid ligand-based and structure-based methodology demonstrates an effective approach for virtual screening that leverages existing SAR and receptor structure information for identifying novel hits for NOP receptor binding. The refined active-state NOP homology models obtained from the enrichment studies can be further used for structure-based optimization of these new chemotypes to obtain potent and selective NOP receptor ligands for therapeutic development.

Indexed as

Molecular Docking SimulationAlgorithmsAnalgesics, OpioidCatalytic DomainCrystallography, X-RayDatabases, ChemicalHigh-Throughput Screening AssaysHumansLigandsNarcotic AntagonistsNociceptin ReceptorPiperidinesProtein BindingProtein Structure, SecondaryReceptors, OpioidResearch DesignAnalgesics, OpioidLigandsNarcotic AntagonistsNociceptin ReceptorOPRL1 protein, humanPiperidinesReceptors, OpioidRhodopsinSmall Molecule Libraries

Identifiers

PMID25148595
PMCPMC4210177
OpenAlexW2048953309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.